Development and Provision of a Polypharmacy Support Service
First written in FY2017. 10 of 13 entries say "Restated". Latest entry: FY2022.
0 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「The insurer information services analyze claims and health-checkup data received from insurers and, to optimize medical expenses, support the preparation of data-health plans and health promotion programs, provide notifications to promote the use of generic drugs, and provide claims review systems. The services have also newly begun providing polypharmacy management services.」
Reconfirms the composition of insurer-focused services, including polypharmacy management services, as part of its business activities. - FY2022-Q2RestatedAnnual report
「In addition, interest in polypharmacy initiatives, defined as addressing drug-related adverse events such as side effects caused by taking many medications, as well as in corporate health management at companies and health insurance societies, is increasing, and demand for data health is expanding across a broad range of areas.」
Reconfirms the increasing interest in polypharmacy initiatives and corporate health management at companies and health insurance societies, as well as the expansion across a broad range of areas of demand for data health. - FY2021RestatedAnnual report
「The insurer information services analyze claims and health-checkup data received from insurers and, to optimize medical expenses, support the preparation of data-health plans and health promotion programs, provide notifications to promote the use of generic drugs, and provide claims review systems. The services have also newly begun providing polypharmacy management services.」
Continues to provide services, including polypharmacy management services, as part of its business activities. - FY2021-Q3RestatedAnnual report
「In addition, interest in polypharmacy initiatives, defined as addressing drug-related adverse events such as side effects caused by taking many medications, as well as in corporate health management at companies and health insurance societies, is increasing, and demand for data health is expanding across a broad range of areas.」
Reconfirms the increasing interest in polypharmacy initiatives and the expansion across a broad range of areas of related demand for data health. - FY2021-Q1RestatedAnnual report
「In addition, interest in polypharmacy initiatives, defined as addressing drug-related adverse events such as side effects caused by taking many medications, as well as in corporate health management at companies and health insurance societies, is increasing, and demand for data health is expanding across a broad range of areas.」
Reconfirms the increasing interest in polypharmacy initiatives and the expansion of demand for data health across a broad range of areas. - FY2020-Q3RestatedAnnual report
「Interest in polypharmacy initiatives, as well as in corporate health management at companies and health insurance societies, is increasing, and demand for data health is expanding across a broad range of areas.」
Reconfirms the expansion across a broad range of areas of demand for data health, including polypharmacy initiatives. - FY2020-Q2RestatedAnnual report
「Interest in polypharmacy initiatives, as well as in corporate health management at companies and health insurance societies, is increasing, and demand for data health is expanding across a broad range of areas.」
Reconfirms the increasing interest in polypharmacy initiatives and the expansion of demand for related services across a broad range of areas. - FY2019RestatedAnnual report
「In September 2018, the company began providing Hiroshima City with a multi-medication information notification service and a support system for pharmacists addressing polypharmacy.」
Reconfirms the provision in Hiroshima City of the multi-medication information notification service and pharmacist support system, launched there, as well as the policy of expanding nationwide. - FY2019-Q3RestatedAnnual report
「Interest in addressing polypharmacy, defined as drug-related adverse events such as side effects caused by taking many medications, has increased in recent years. The group has also begun developing and providing polypharmacy-related services with the aim of making them a new core business.」
Reconfirms the policy of making polypharmacy-related services a new core business and the launch of service development and provision. - FY2019-Q2RestatedAnnual report
「Interest in addressing polypharmacy, defined as drug-related adverse events such as side effects caused by taking many medications, has increased in recent years. The group has also begun developing and providing polypharmacy-related services with the aim of making them a new core business.」
Reconfirms the policy of making polypharmacy-related services a new core business and the launch of their development and provision. - FY2019-Q1AdvancedAnnual report
「Interest in addressing polypharmacy, defined as drug-related adverse events such as side effects caused by taking many medications, is also increasing. The company has begun providing polypharmacy-related services with the aim of making them a new core business. The company is also explaining these services to medical care wide-area unions for the late-stage elderly nationwide, mainly to generate future orders, and is pursuing sales activities.」
Explicitly states that polypharmacy-related services have been launched and that sales efforts are being pursued, mainly with medical care wide-area unions for the late-stage elderly nationwide, with the aim of making them a new core business. - FY2018AdvancedAnnual report
「In September 2018, the company began providing Hiroshima City with a polypharmacy support system for pharmacists, in addition to its multi-medication information notification service. It plans to roll out both the business and the system nationwide.」
Describes the launch in Hiroshima City of the pharmacist support system in addition to the multi-medication information notification business, and the policy of expanding nationwide. - FY2017First statedAnnual report
「In particular, the company will develop and provide services to address polypharmacy, which has attracted attention in recent years.」
Plans a new service that centrally captures medication information from claims data and provides it to relevant organizations to address medication costs and adverse drug events associated with polypharmacy.